Ad

Regulators broadly agree that they should categorise the risks of AI for different purposes so that "we don't over-regulate where the use of AI may be just a background process, and not impact the benefit-risk balance for a medicine." (Photo: NVinacco)

Keeping an eye on AI-powered drugs

Health in a post-pandemic EU

Health & Society

by Gaby Galvin, Amsterdam,

Medicines created using artificial intelligence could be coming to a pharmacy counter near you — but just how soon depends on whether they live up to the hype in clinical tests.

AI may have become the buzzword of 2023, but major pharmaceutical companies and startups alike have been investing in the tech

To read this story, log in or subscribe

Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.

Already a member? Login

Health in a post-pandemic EU Health & Society

Author Bio

Gaby Galvin is a freelance journalist based in Amsterdam.

Related articles

Religious minority abused at EU-funded centre in Turkey: witness

Power grid spending needs to double to €600bn, IEA warns

COP27 is where EU starts paying for colonial climate change

Regulators broadly agree that they should categorise the risks of AI for different purposes so that "we don't over-regulate where the use of AI may be just a background process, and not impact the benefit-risk balance for a medicine." (Photo: NVinacco)

Tags

Health in a post-pandemic EU Health & Society

Author Bio

Gaby Galvin is a freelance journalist based in Amsterdam.

Ad

Related articles

Religious minority abused at EU-funded centre in Turkey: witness

Power grid spending needs to double to €600bn, IEA warns

COP27 is where EU starts paying for colonial climate change

Ad

Ad

Latest News